BioVersys Enrolls First Patient in Phase 2b Trial of BV100 Antibiotic
Bitget2026/10/29 06:01- BioVersys began enrolling patients in its Phase 2b RIV-CARE trial of BV100 for serious infections caused by carbapenem-resistant Acinetobacter bacteria.
- The approximately 100-patient trial compares BV100-based antibiotic combinations with best available therapy in settings with high drug resistance.
- A previous Phase 2 trial recorded 28-day mortality of 25% with BV100 and polymyxin B, versus 60% with best available therapy.
- Interim RIV-CARE results are expected in the first half of 2027, with final patient enrollment anticipated toward year-end.
- The study complements the ongoing Phase 3 RIV-TARGET trial; initial regulatory submissions for BV100 are anticipated by mid-2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bank of Japan minutes turn hawkish: Most members believe a rate hike is needed soon, with a 70% probability of a hike in December
Minutes from the Bank of Japan show that several members believe a rate hike is needed in the near term, with a roughly 70% probability of an increase in December. Core inflation has met the target for the first time in 30 years, and the current policy rate stands at 1.25%.
Former Chainlink Product Marketing Director Michael Robinson joins Monad Foundation
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Crypto prices
More
